Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 14/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | AGL | P35573 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LCT | P09848 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172380 | 1.00 | GBA1 (0.60) | GBA1GAAMGAMAGLTDP1 | |
| SCHEMBL8180629 | 1.00 | GBA1 (0.60) | GBA1GAAMGAMAGLTDP1 | |
| SCHEMBL18975425 | 0.88 | GBA1 (0.50) | GBA1GAAMGAM | |
| SCHEMBL7403991 | 0.86 | — | — | |
| SCHEMBL7022461 | 0.86 | — | — | |
| SCHEMBL7020593 | 0.86 | — | — | |
| SCHEMBL12715769 | 0.86 | — | — | |
| SCHEMBL14514284 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL9090519 | 0.84 | GAA (0.43) | GBA1GAAMGAMAGLTDP1 | |
| SCHEMBL25753303 | 0.80 | GBA1 (0.40) | GBA1GAAMGAMAGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| US-6046214-A | USEFUL IN TREATMENT AND/OR PREVENTION OF DIABETES, AND ESPECIALLY NON-INSULIN DEPENDENT DIABETES (NIDDM OR TYPE 2 DIABETES) INCLUDING OVERNIGHT OR MEAL TREATMENT AND TREATMENT OR PREVENTION OF LONGTERM COMPLICATIONS, SUCH AS RETINOPATHY | NOVO NORDISK A/S (DK) | 2000-04-04 | — | — | US | claimed |
| EP-0983239-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050359-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-11-12 | — | — | WO | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| EP-0749423-B1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK AS (DK) | 2003-06-18 | — | — | EP | disclosed |
| US-6046214-A | USEFUL IN TREATMENT AND/OR PREVENTION OF DIABETES, AND ESPECIALLY NON-INSULIN DEPENDENT DIABETES (NIDDM OR TYPE 2 DIABETES) INCLUDING OVERNIGHT OR MEAL TREATMENT AND TREATMENT OR PREVENTION OF LONGTERM COMPLICATIONS, SUCH AS RETINOPATHY | NOVO NORDISK A/S (DK) | 2000-04-04 | — | — | US | disclosed |
| EP-0983239-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-03-08 | — | — | EP | disclosed |
| US-5863903-A | ANTIDIABETIC AGENT | NOVO NORDISK A/S (DK) | 1999-01-26 | — | — | US | disclosed |
| WO-1998050359-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-11-12 | — | — | WO | disclosed |
| EP-0749423-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024391-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885MGAM 13/4885 |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885MGAM 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.